Neoral® conversion from Sandimmune® in maintenance renal transplant patients: An individualized approach

Journal of the American Society of Nephrology

Volumn 9, Issue 7, 1998, Pages 1293-1300

  Curtis, John J ^a,c   Lynn, Melissa ^b   Jones, Patricia A ^a  

^a University of Alabama at Birmingham   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; NEORAL R; SANDIMMUNE R; UNCLASSIFIED DRUG; CREATININE; CYCLOSPORIN; CYCLOSPORIN A, MEALA(3) PHE(7) SER(8); CYCLOSPORIN A, MEALA(3)-PHE(7)-SER(8)-; CYCLOSPORIN DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ALLOGRAFT; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; FOLLOW UP; GRAFT REJECTION; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MICROEMULSION; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; ADULT; AGED; BLOOD; DRUG ADMINISTRATION; FEMALE; GRAFT SURVIVAL; MALE; MIDDLE AGED; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; CREATININE; CYCLOSPORINE; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031595421     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Milford EL, Kirkman RL, Tilney NL, Strom TB, Carpenter CB: Clinical experience with cyclosporine and azathioprine at Brigham and Women's Hospital. Am J Kidney Dis 5: 313-317, 1985
2. Williams R, Blackburn A, Neuberger J, Caine RY: Long-term use of cyclosporine in liver grafting. Q J Med 57: 897-905, 1985
3. Bolman RE, Elick B, Olivari MT, Ring WS, Arentzen CE: Improved immunosuppression for heart transplantation. J Heart Transplant 4: 315-318, 1985
4. Burke JJ, Pirsch JD, Ramos EL, Salomon DR, Stablein DM, Van Buren DH, West JC: Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 331: 358-363, 1994
5. Bennett WM: The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 43[Suppl 1]: S3-S7, 1995
6. Tsang WK, Ho YW, Tong KL, Chan WH, Chan A: Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: Conversion study in stable renal transplant recipients. Transplant Proc 28: 1330-1332, 1996
7. Mueller EA, Kovarik JM van Bree JB, Lison AE, Kutz K: Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients: A concentration-controlled comparison with the commercial formulation. Transplantation 57: 1178-1182, 1994
8. Kovarik JM, Mueller EA van Bree JB, Fluckiger SS, Lange H, Schmidt B, Boesken WH, Lison AE, Kutz K: Cyclosporine pharmacokinetics and variability from a microemulsion formulation: A multicenter investigation in kidney transplant patients. Transplantation 58: 658-663, 1994
9. Bokenkamp A, Offner G, Hoye PF, Vester U, Wonigeit K, Brodehl J: Improved absorption of cyclosporin A from a new microemulsion formulation: Implications for dosage and monitoring. Pediatr Nephrol 9: 196-198, 1995
10. Neumayer HH, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J: Clinical experience transferring kidney transplant patients from Sandimmune to Sandimmune Neoral: Results after 3 months. Clin Nephrol 43[Suppl 1]: S27-S32, 1995
11. Wahlberg J, Wilczek HE, Fauchald P, Nordal KP, Heaf JG, Olgaard K, Hansen JM, Lokkegaard H, Mueller EA, Kovarik JM: Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 60: 648-652, 1995
12. Hansen BL, Rohr N, Svendsen V, Birkeland SA: Hypertension is not a complication in cyclosporine-A monotherapy. Int Urol Nephrol 21: 91-95, 1989
13. Brinker KR, Dickerman RM, Gonwa TA, Hull AR, Langley JW, Long DL, Nesser DA, Trevino G, Velez RL, Vergne-Marini PJ: A randomized trial comparing double-drug and triple-drug therapy in primary cadaveric renal transplants. Transplantation 50: 43-49, 1990
14. Diethelm AG, Laskow DA, Hudson SL, Deierhoi MH, Barber WH, Barger BO, Julian BA, Gaston RS, Curtis JJ: Benefits of quadruple immunosuppressive therapy in recipients of living related donor kidneys: A review of 855 operations. Ann Surg 215: 606-616, 1992
15. Hardie IR, Tiller DJ, Mahony JF, Miach PJ, Thomson NM, Thatcher GN, Rigby RJ, Menzies BL: Optimal combination of immunosuppressive agents for renal transplantation: First report of a multicentre, randomised trial comparing cyclosporine + prednisolone with cyclosporine + azathioprine and with triple therapy in cadaver renal transplantation: The Australian Collaborative Trials Committee. Transplant Proc 25: 583-584, 1993
16. Aichberger C, Eberl T, Riedmann B, Pernthaler H, Ofner D, Konigsrainer A, Margreiter R: Long-term outcome after switch from cyclosporine-based triple-drug immunosuppression to double therapy at three months. Clin Transplant 10: 209-212, 1996
17. Bartucci MR, Koshla B, Fleming-Brooks S, Weigel K, Donley V, Schulak JA, Knauss TC, Hricik DE: Renal function following conversion from Sandimmune to Neoral in stable renal transplant recipients. J Transplant Coord 7: 78-81, 1997
18. Kupin W, Venkat KK, Goggins M, Mozes M, Abouljoud M, Escobar F: Elective conversion of Sandimmune to Neoral in stable renal transplant recipients [Abstract]. American Society of Transplant Physicians, 16th Annual Scientific Meeting, 1997
19. Curtis JJ, Jones PA, Barbeito R, Julian BA, Gaston RS, Sanders CE Jr: Predictors of dose change when converting kidney transplant patients from Sandimmune to Neoral [Abstract], American Society of Transplant Physicians, 15th Annual Scientific Meeting, 1996
20. Lindholm A, Welsh M, Alton C, Kahan BD: Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability. Clin Pharmacol Ther 52: 359-371, 1992
21. First MR, Schroeder TJ, Monaco AP, Simpson MA. Curtis JJ, Armenti VT: Cyclosporine bioavailability: Dosing implications and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant 10: 55-59, 1996
22. Neumayer HH, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J: Conversion from Sandimmune to Sandimmune Neoral in patients with stable renal allografts: Results after 1 month. Transplant Proc 26: 2944-2948, 1994
23. Barone G, Bunke CM, Choc MG Jr, Hricik DE, Jin JH-J, Klein JB, Marsh CL, Min DI, Pescovitz MD, Pollak R, Pruett TL, Stinson JB, Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL: Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Transplant Proc 28: 2183-2186, 1996
24. Chapman JR, O'Connell PJ, Bovington KJ, Allen RDM: Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption. Transplant Proc 28: 2293-2295, 1996
25. Hoyer PF, Boekenkamp A, Vester U, Offner G, Brodehl J: Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients. Transplant Proc 28: 2259-2261, 1996
26. Hricik DE, Bartucci MR, Knauss TC, Schulak JA: Renal function after conversion from Sandimmune to Neoral in stable renal transplant recipients [Abstract]. J Am Soc Nephrol 7: 1912, 1996
27. Lokkegaard H, Admundsson P, Clausen P, Dieperink H, Hansen JM, Heaf J, Jensen SB, Kornerup HJ, Madsen S, Pedersen EB, Poulsen JV, Rasmussen K: Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients. Transplant Proc 28: 2199-2201, 1996
28. Loo CS, Morad Z, Lim TO, Fan KS, Suleiman AB: A randomized, controlled trial to assess the safety of switching stable renal transplant patients from Sandimmun to Sandimmun Neoral. Transplant Proc 28: 1328-1329, 1996
29. Moore RH, for the UK Neoral Study Group: UK multicentre study to assess the safety and tolerability of Neoral in stable renal transplant patients. Transplant Proc 28: 2202-2203, 1996
30. Offermann G, Korn A, for the German Neoral Study Group: Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. Transplant Proc 28: 2204-2206, 1996
31. Steinmuller DR, Dougherty J, Coutee J, Surek D, Sweis G, Lewis R: The effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients [Abstract]. American Society of Transplant Physicians, 15th Annual Scientific Meeting, 1996